Biogen said it is not worried about competing with Eli Lilly as they both try to roll out drugs to treat the early stages of Alzheimer’s disease.
Biogen CEO Christopher Viehbacher said Eli Lilly’s decision to stop dosing the drug after it clears a certain amount of toxic amyloid brain plaque in a patient may not be the best approach.
Eli Lilly and Biogen may need to consider rolling out maintenance doses that will keep brain plaque levels low, the executive said during a Q1 2023 earnings call.
